Review
CRISPR/Cas13: A potential therapeutic option of COVID-19

https://doi.org/10.1016/j.biopha.2020.110738Get rights and content
Under a Creative Commons license
open access

Highlights

  • The novel coronavirus disease (COVID-19) is a global issue.

  • CRISPR/Cas13 is a potential diagnostic method of COVID-19.

  • CRISPR/Cas13 and CRISPR/deadCas13 are the potential therapeutic candidates of COVID-19.

Abstract

The novel coronavirus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can be considered as the most important current global issue, as it has caused the novel coronavirus disease (COVID-19) pandemic, which has resulted in high mortality and morbidity rates all around the world. Although scientists are trying to discover novel therapies and develop and evaluate various previous treatments, at the time of writing this paper, there was no definite therapy and vaccine for COVID-19. So, as COVID-19 has called ideas for treatment, controlling, and diagnosis, we discussed the application of Clustered Regularly Interspaced Short Palindromic Repeats/Cas13 (CRISPR/Cas13) as a treatment of COVID-19, which received less attention compared with other potential therapeutic options.

Keywords

CRISPR/Cas13
CRISPR/dead Cas13
COVID-19
SARS-CoV-2
Treatment

Cited by (0)